Clearmind Medicine Files India Patent for Alcohol Use Disorder Drug
Ticker: CMND · Form: 6-K · Filed: Mar 27, 2026 · CIK: 0001892500
Sentiment: neutral
Topics: patent, pharmaceuticals, drug-development, international
TL;DR
Clearmind files India patent for CMND-101, a potential alcohol use disorder treatment.
AI Summary
Clearmind Medicine Inc. filed a Form 6-K on March 27, 2026, reporting a patent application filed in India for its novel psychedelic compound CMND-101. This compound is being developed for the treatment of alcohol use disorder. The filing also includes a press release detailing this development.
Why It Matters
This patent filing in India is a significant step for Clearmind Medicine as it seeks to protect its intellectual property for a potential new treatment for alcohol use disorder, a major global health issue.
Risk Assessment
Risk Level: medium — The company is in the early stages of patent filing and drug development, with significant clinical and regulatory hurdles ahead.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Filer of the 6-K report
- CMND-101 (drug_candidate) — Novel psychedelic compound for alcohol use disorder
- India (country) — Jurisdiction for patent application
- March 27, 2026 (date) — Filing date of the 6-K report
FAQ
What is the specific nature of the patent application filed by Clearmind Medicine in India?
Clearmind Medicine filed a patent application in India for its novel psychedelic compound, CMND-101, which is being developed for the treatment of alcohol use disorder.
When was this patent application filed?
The patent application was filed in India, as reported in a Form 6-K filed on March 27, 2026.
What is the intended use for the compound CMND-101?
CMND-101 is being developed by Clearmind Medicine for the treatment of alcohol use disorder.
What type of SEC filing is this document?
This document is a Form 6-K, which is a report of a foreign issuer.
Where is Clearmind Medicine Inc. based?
Clearmind Medicine Inc. has its mailing and business address at 101-1220 West 6th Avenue, Vancouver, British Columbia, Z4 V6H1A5.
Filing Stats: 201 words · 1 min read · ~1 pages · Grade level 13.4 · Accepted 2026-03-27 07:40:18
Filing Documents
- ea0283772-6k_clearmind.htm (6-K) — 10KB
- ea028377202ex99-1.htm (EX-99.1) — 11KB
- ea028377202_ex99-1img1.jpg (GRAPHIC) — 4KB
- 0001213900-26-035150.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Clearmind Medicine, Inc. (Registrant) Date: March 27, 2026 By: /s/ Adi Zuloff-Shani Name: Adi Zuloff-Shani Title: Chief Executive Officer 3